fda approves first oral glp-1 obesity drug august 1 2025 Orforglipron, approved as Foundayo on April 1, 2026, adds another option for chronic weight management in adults with or overweight plus at least one weight-related condition. The clinical relevance The first ever FDA-approved GLP-1

the two FrontRow honchos even went to California to badger their US manufacturer, which is currently upgrading to cope with demand

In some high-profile cases, individuals have experienced cardiac arrest (which is different from a heart attack) following unregulated, high-dose injections

Compositional changes in the vaginal bacterial microbiome of healthy pregnant women across the three gestational trimesters in Ismailia, Egypt

Additionally, IF increases brain-derived neurotrophic factor (BDNF) and leads to a reduction in blood pressure [9, 77, 78]

Trust your treatment to a provider committed to quality and safety